New statement released by anticoagulation forum

New statement released by anticoagulation forum
The Anticoagulation Forum has endorsed a new consensus statement aimed at optimizing the delivery of anticoagulation therapy to inpatients; the statement has been published in the May issue of the Annals of Pharmacotherapy.

(HealthDay)—The Anticoagulation Forum has endorsed a new consensus statement aimed at optimizing the delivery of anticoagulation therapy to inpatients; the statement has been published in the May issue of the Annals of Pharmacotherapy.

Edith A. Nutescu, Pharm.D., from the University of Illinois at Chicago, and colleagues from the Anticoagulation Forum reviewed the medical literature to identify published articles relating to the standards of practice, national guidelines, patient safety initiatives, and regulatory requirements pertaining to anticoagulant use in the inpatient setting.

The recommendations endorsed by the Anticoagulation Forum and included in the statement are aimed at informing the development of coordinated care systems containing elements with demonstrated benefit in improvement of outcomes. The paper addresses the areas of process, accountability, integration, standards of practice, provider education and competency, patient education, care transitions, and outcomes.

"This document provides consensus guidelines for anticoagulant therapy in the inpatient setting and serves as a companion document to prior guidelines relevant for outpatients," the authors write.

More information: Abstract
Full Text

add to favorites email to friend print save as pdf

Related Stories

New blood-thinner measures may cut medication errors

May 22, 2013

Blood thinners are the preferred treatment option to prevent heart attacks, blood clots and stroke, but they are not without risk, and not just because of their side effects. These high-risk drugs, known as anticoagulants, ...

Recommended for you

Express Scripts turns to AbbVie in huge hepatitis C deal

3 hours ago

The nation's largest pharmacy benefits manager is throwing its weight into a fight over the high cost of treating hepatitis C, saying it will cover a drug from AbbVie while pulling back on those from rival drugmakers.

FDA OKs Cubist antibiotic for serious infections

Dec 20, 2014

The Food and Drug Administration has approved a new medicine to fight complex infections in the abdomen and urinary tract, the fourth antibiotic the agency has approved since May.

Xtoro approved for swimmer's ear

Dec 18, 2014

(HealthDay)—Xtoro (finafloxacin otic suspension) eardrops have been approved by the U.S. Food and Drug Administration to treat swimmer's ear, clinically known as acute otitis externa.

Drug interaction identified for ondansetron, tramadol

Dec 18, 2014

(HealthDay)—In the early postoperative period, ondansetron is associated with increased requirements for tramadol consumption, according to a review and meta-analysis published online Dec. 10 in Anaesthesia.

New system targets germs in donated blood plasma

Dec 17, 2014

(HealthDay)—A new system designed to eliminate germs in donated blood plasma and reduce the risk of transmitting a plasma-borne infection has been approved by the U.S. Food and Drug Administration.

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.